US · PRENW
Prenetics Global Limited
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Quarry Bay
- Website
- prenetics.com
Price · as of 2024-12-31
$0.02
Market cap 294.94K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $2.35 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $3,115.68 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Prenetics Global Limited's (PRENW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.02
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRENW | Prenetics Global Limited | $0.02 | 294.94K | — | — | — | — | — | — | — | — | — | — | 50.29% | -157.23% | -151.22% | -26.44% | -33.35% | -21.30% | 0.03 | -237.16 | 2.36 | 1.87 | 0.90 | -3477.00% | 4083.00% | 10399.00% | — | -0.79 | -24.02% | — | 0.00% | — | — | — | — | — |
| BCTXW | BriaCell Therapeutics Cor… | $0.05 | 333.36K | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -237.76% | -2090.29% | -192.98% | 0.00 | -735.71 | 5.01 | 4.69 | 0.29 | 191519.00% | — | 1459.00% | — | -7.08 | -1560.53% | — | 0.00% | — | — | — | — | — |
| CELU | Celularity Inc. | $1.84 | 42.25M | +2,561% | -73% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| IVF | NAYA Biosciences, Inc. Co… | $0.52 | 486.23K | +299,547% | +14,298,596% | — | — | -3.04 | 2.17 | 4.23 | -5.15 | -0.62 | -0.96 | 44.00% | -124.40% | -139.25% | -133.37% | -56.16% | -28.01% | 0.78 | -7.69 | 0.07 | 0.05 | -1.28 | 48841.00% | 11625.00% | -3926.00% | -11.43% | -0.17 | -21.88% | 0.00% | 0.00% | 0.00% | -4.53 | -11.65 | 5.63 | -2.40 |
| NUWE | Nuwellis, Inc. | $2.80 | 2.53M | +14,836% | +2,133% | — | — | -6.49 | 11.10 | 8.29 | -6.45 | — | 11.10 | 66.66% | -125.72% | -127.75% | -229.24% | -1021.66% | -113.73% | 0.08 | -1.96 | 3.46 | 2.67 | 0.43 | -9778.00% | -140.00% | -4693.00% | -13.32% | -3.75 | -897.35% | 0.00% | 0.00% | 2.08% | -6.18 | -7.04 | 7.77 | -31.39 |
| REVB | Revelation Biosciences, I… | $1.08 | 1.84M | — | — | — | — | 0.00 | 0.00 | — | 0.67 | — | 0.00 | 0.00% | — | — | -201.08% | 1657.76% | -153.82% | 0.08 | — | 5.41 | 5.36 | 0.67 | -7268.00% | — | 4498931.00% | -103262.37% | -4.14 | 1511.33% | 74316.81% | -66.80% | 198525.74% | 1.10 | 1.20 | — | -7.64 |
| SABS | SAB Biotherapeutics, Inc. | $3.18 | 33.11M | +303% | -80% | — | +3,500% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
| SRZN | Surrozen, Inc. | $12.42 | 106.44M | — | -62% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
About Prenetics Global Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
- CEO
- Sheng Wu Yeung
- Employees
- 285
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.02) − 1 = — (DCF, example).